Investigating the Anti-inflammatory Effects of Frondanol in Adults With Inflammatory Bowel Disease
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This is a pilot, prospective, double-blinded, two-arm, randomized controlled trial of the
efficacy of Frondanol in comparison to placebo in decreasing bowel inflammation in patients
with a clinical diagnosis of inflammatory bowel disease who are in remission and on standard
of care treatment.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Mohammed Bin Rashid University of Medicine and Health Sciences
Collaborators:
Dubai Health Authority Mediclinic Middle East Rashid Hospital